- Stress and anxiety symptoms: pooled analyses of short, mostly small randomised trials favour ashwagandha over placebo, but results vary widely between trials and one analysis found no clear effect on perceived stress (C: limited).
- Cortisol (a blood or saliva stress hormone): lower cortisol was seen consistently in pooled analyses. This is a laboratory marker, not a symptom (B: moderate).
- Sleep: a small benefit for sleep quality and sleep-onset time is reported, mostly in five small trials and more clearly in people with insomnia (C: limited).
- Depression: one recent analysis reports benefit, but the figures are implausibly large and the trials are few (D: weak).
- Memory and attention: a 2026 meta-analysis reports small gains, in a mix of study populations (C: limited).
- Exercise and muscle: possible gains in aerobic capacity (C: limited). Added strength from resistance training is not established (D: weak).
- Testosterone, fertility and blood glucose: testosterone rises modestly in some trials, with unclear meaning (C: limited). Benefit for sexual function or fertility is unproven (D: weak). Any effect on glucose is tiny and very low certainty (D: weak).
- Safety: most trials in healthy adults report mild side effects only. But the TGA warns of very rare liver injury, and people with liver disease should avoid ashwagandha (B: moderate that the liver signal is real). Pregnancy and breastfeeding have insufficient human evidence (F).
Last reviewed: 19 November 2026 · Written by SD, pharmacist · No products were supplied and no commission is earned from this review.
Does ashwagandha reduce stress and improve sleep?
Ashwagandha (Withania somnifera) is a shrub whose root has long been used in Ayurvedic medicine. In Australia it is sold as a supplement, usually as a concentrated root extract in capsules or tablets, for stress, sleep, energy, mood, exercise performance and hormone balance. The Therapeutic Goods Administration (TGA) reports that about 320 medicines on the Australian Register of Therapeutic Goods (ARTG) contain it, and that you can buy it in supermarkets, health food shops and pharmacies without a prescription or health professional advice.[18]
This review asks a narrow question: in randomised trials in adults, does a standardised ashwagandha extract change stress, anxiety, sleep and other outcomes people care about compared with placebo, and what does the TGA say about safety? It is a targeted editorial review, not a formal systematic review. We searched PubMed on 19 November 2026 for systematic reviews, meta-analyses and randomised trials of ashwagandha, and read the TGA’s current safety communications.
The short answer
For stress and anxiety, there is a plausible, probably modest benefit, but low confidence (C: limited). Pooled analyses of randomised trials report lower stress and anxiety scores than placebo. For example, a 2024 meta-analysis of nine trials (558 people) found an average drop of 4.7 points on the Perceived Stress Scale and 2.2 points on the Hamilton Anxiety Scale compared with placebo.[2] A 2022 meta-analysis of 12 trials (1,002 people) reported large standardised effects, but with very high heterogeneity (I² of 83% to 94%), and its authors rated the certainty of evidence as low for both outcomes.[1] A 2025 meta-analysis that required longer trials and used a risk-of-bias tool found no clear effect on perceived stress (SMD −0.36, 95% CI −1.19 to 0.47).[3] Different trial selections gave different answers, which is itself a sign of fragile evidence.
The most consistent finding is a lower cortisol level. The 2025 analysis found an average fall of 1.16 µg/dL (95% CI −1.64 to −0.69), and the 2024 analysis found a reduction as well (B: moderate for the biomarker effect).[2][3] Cortisol is a stress hormone, but a lower reading is not the same as feeling less stressed, and the 2025 analysis highlights the “disconnect” between the two.[3]
For sleep, a 2021 meta-analysis of five trials (400 people) found a small-to-moderate improvement in overall sleep (SMD −0.59, 95% CI −0.75 to −0.42), clearer in adults diagnosed with insomnia, with doses of 600 mg a day or more, and with treatment of eight weeks or longer (C: limited).[5] Five small trials are a thin base. Other popular uses are weaker: memory and attention (C: limited), aerobic fitness (C: limited), strength from resistance training (D: weak), testosterone (C: limited), sexual function or fertility (D: weak), depression (D: weak) and blood glucose (D: weak).
The main safety message comes from the TGA. In very rare cases, ashwagandha products have been linked to liver injury, and the TGA says people with existing liver disorders should avoid them.[18][19] Most cases recover after stopping the product, but some have needed hospital care, and international reports include liver failure and one transplant.[18][20][21] There is not enough human evidence to say whether ashwagandha is safe in pregnancy or breastfeeding (F: insufficient).
How might it work?
Ashwagandha root contains withanolides and other compounds. In animal and laboratory studies they affect the hypothalamic–pituitary–adrenal (HPA) axis, the system that controls cortisol, and some pathways involved in inflammation and nerve signalling. A 60-day trial in stressed adults reported falls in morning cortisol and in DHEA-S, an adrenal hormone, on ashwagandha compared with placebo, which the authors linked to a moderating effect on the HPA axis.[7] These are proposed mechanisms. They explain how an effect could occur. They do not show that a capsule will change how you feel, and the same hormone-modulating action is the reason some safety reports exist (see below).
What the human trials show
Systematic reviews and meta-analyses
| Review | What was pooled | Main finding | Caveats |
|---|---|---|---|
| Akhgarjand 2022[1] | 12 RCTs, 1,002 adults aged 25 to 48; searches to December 2021 | Lower anxiety (SMD −1.55, 95% CI −2.37 to −0.74) and stress (SMD −1.75, −2.29 to −1.22) than placebo. Dose–response analysis suggested stress benefit at 300–600 mg a day | Very high heterogeneity (I² 94% for anxiety, 83% for stress). The authors graded the certainty of evidence as low for both outcomes |
| Arumugam 2024[2] | 9 RCTs, 558 patients; searches January 2000 to January 2022 | Perceived Stress Scale: mean difference −4.72 (95% CI −8.45 to −0.99). Hamilton Anxiety Scale: −2.19 (−3.83 to −0.55). Serum cortisol: −2.58 (−4.99 to −0.16) | Four trials reported mild to moderate adverse events. Wide confidence intervals. Authors note that long-term safety data are lacking |
| Albalawi 2025[3] | 7 RCTs on cortisol and 6 on perceived stress (488 participants); oral doses of 250 mg a day or more for at least 2 weeks | Cortisol fell by 1.16 µg/dL (95% CI −1.64 to −0.69). No significant effect on perceived stress (SMD −0.36, −1.19 to 0.47) | Risk of bias generally moderate and some trials lacked allocation concealment. Short trials |
| Alsanie 2026[4] | 22 RCTs of mental health outcomes, with dose–response analysis | Reports improvement in stress, depression and anxiety | The reported standardised effects (about −6 to −7) are far larger than those seen in other analyses, which suggests heterogeneity or small-study problems. We do not rely on these figures |
| Cheah 2021[5] | 5 RCTs, 400 adults; sleep outcomes | Small-to-moderate improvement in overall sleep (SMD −0.59, 95% CI −0.75 to −0.42; I² 62%). Also better mental alertness on rising and lower anxiety, with no effect on quality of life | Few, small trials. Larger effect in people with insomnia, at 600 mg a day or more and at 8 weeks or longer. The authors note limited serious-adverse-event data |
The reviews do not all agree, and the largest effects come from analyses with the most heterogeneity. That pattern usually means the pooled number is less trustworthy than it looks.
Key randomised trials
| Trial | Participants and design | Dose and form | Main finding |
|---|---|---|---|
| Chandrasekhar 2012[6] | 64 adults with a history of chronic stress; single-centre, double-blind, placebo-controlled, 60 days | 300 mg twice daily of a high-concentration full-spectrum root extract | Lower scores on stress scales (P < 0.0001) and lower serum cortisol (P = 0.0006) than placebo. Adverse effects were mild and similar between groups |
| Salve 2019[8] | 60 stressed adults with a Perceived Stress Scale score above 20; 8-week, three-arm placebo-controlled trial | 125 mg or 300 mg root extract, twice daily, or placebo | Perceived Stress Scale scores fell more than on placebo at both doses (P < 0.05 at 250 mg a day; P < 0.001 at 600 mg a day). Serum cortisol was lower at both doses, and sleep quality was better than on placebo |
| Lopresti 2019[7] | 60 stressed, healthy adults; 60-day randomised, double-blind, placebo-controlled | 240 mg a day of a standardised extract | Lower Hamilton Anxiety score than placebo (P = 0.040). The Depression Anxiety Stress Scale change was not significant (P = 0.096). Morning cortisol and DHEA-S fell more than on placebo. No adverse events reported |
| Langade 2021[9] | 80 adults (40 healthy, 40 with insomnia); 8-week randomised, double-blind, placebo-controlled | Root extract versus placebo | Improved sleep-onset time, sleep efficiency, total sleep time, wake after sleep onset, sleep quality and anxiety scores, with larger gains in the insomnia group. Well tolerated |
All four trials are small (60 to 80 people) and lasted about 8 to 9 weeks. Most studied a single, standardised root extract rather than the range of products on the market. Many people in the trials were healthy adults with self-reported stress rather than people diagnosed with an anxiety disorder, so the results should not be applied to clinical anxiety.
What dose was studied — and what is in a typical product?
Trial doses ranged from about 125 to 600 mg a day of standardised root extract, taken for periods from a single dose to about six months.[17] The doses in the trials above were 240 mg once daily, 300 mg twice daily, or 125 and 300 mg twice daily.[6][7][8] The 2021 sleep analysis found larger effects at 600 mg a day or more.[5] These numbers refer to the extract in each trial, not to “ashwagandha” in general. The TGA notes that extraction method, extraction ratio and whether the root or leaf is used all change the composition of a product, and that listed medicines in Australia have no specific dose or preparation limits for this herb.[18] A capsule labelled with a similar milligram figure may therefore not match what was tested.
Other outcomes people hope ashwagandha will improve
Depression
The only pooled estimate we found for depression is in the 2026 mental-health meta-analysis, which reported benefit but with implausibly large effect sizes (see the table above).[4] Stress and anxiety trials usually measured depression only as a secondary outcome. We grade a benefit for depression D: weak. It is not a substitute for treatment in people with depression.
Memory and attention
A 2026 meta-analysis of 20 trials (1,249 participants) reported small to moderate improvements in memory (SMD 0.52, 95% CI 0.27 to 0.78), attention and processing speed (0.29, 0.07 to 0.51) and executive function. Only one study assessed global cognition. The authors rated most included studies as high or moderate quality.[13] This is a single, recent analysis that pooled mixed populations and tests, so we grade it C: limited until it is replicated.
Exercise, strength and muscle
A 2026 meta-analysis of 13 trials (599 participants) found better overall exercise performance with ashwagandha (Hedges’ g 0.47, 95% CI 0.25 to 0.69), most consistently for aerobic endurance (g 0.54), but the 95% prediction interval (−0.40 to 1.33) crossed zero, meaning a future trial could plausibly find no benefit.[10] An earlier meta-analysis of four trials (142 participants) found a higher maximal oxygen uptake (mean difference 3.00, 95% CI 0.18 to 5.82) with high heterogeneity.[11] Together these support C: limited for aerobic performance.
For adding strength or muscle to a resistance-training programme, a 2026 meta-analysis pooled only three trials (161 people) and found gains in bench press and lower-body strength that were no longer statistically significant under a more conservative method. Each estimate depended on one influential trial and the certainty was low to very low. The authors concluded that the evidence does not establish a meaningful benefit and there was no dependable effect on body fat.[12] We grade this D: weak.
Testosterone, fertility and sexual function
The 2026 cognitive and physical function meta-analysis reported a small rise in testosterone (SMD 0.33, 95% CI 0.13 to 0.54).[13] A 16-week crossover trial in 57 overweight men aged 40 to 70 found a 14.7% greater rise in testosterone than on placebo, but no significant between-group differences in fatigue, vigour, sexual well-being or cortisol.[14] A systematic review of safety trials noted that testosterone increases stayed within physiological ranges.[17] A rise in a hormone level has not been shown to translate to better sexual function or fertility. A 2026 systematic review of reproductive outcomes mixed animal and human research and concluded only that there was potential.[15] We grade testosterone C: limited and sexual function or fertility D: weak.
Blood glucose
A 2026 meta-analysis of 11 trials (667 participants) found fasting glucose about 3 mg/dL lower than placebo (95% CI −5.61 to −0.58), with substantial heterogeneity. HbA1c was imprecise and inconclusive. The authors rated certainty as very low and said it precluded clinical recommendations.[16] We grade this D: weak.
Clinical relevance: will you notice?
- Stress and anxiety: on average, the trials suggest a small to moderate improvement over about 8 weeks, but the confidence intervals are wide and individual results will vary. Some people may notice little. Ashwagandha is not an evidence-based replacement for care in people with an anxiety disorder.
- Sleep: you might fall asleep a little faster or sleep a bit better, particularly if you have insomnia, but this rests on five small trials.
- Cortisol: a lower number in a test does not mean you will feel calmer, and the analyses disagree on whether perceived stress itself falls.
- Gym and muscle: do not expect noticeable extra strength or muscle. Some endurance benefit is possible but uncertain.
- Placebo response: stress and sleep scores are subjective and improve on placebo in most trials, so small differences between groups are easy to over-read.
Safety and interactions: a pharmacist’s checklist
- Liver injury (the TGA warning). The TGA published a safety advisory in February 2024 and an update on 7 July 2026. In very rare cases, liver injury has been reported after consuming products containing Withania somnifera. By July 2026 the TGA had received 11 reports with enough information to suggest possible liver injury. In 6 of the 11 there were no other ingredients likely to have contributed. In 4 of those 6, the suspected product was a listed medicine on the ARTG, and 2 of those 4 needed hospitalisation. No Australian fatalities or liver transplants have been reported, but at least 4 international case reports describe liver failure (one needing a transplant), and 3 deaths occurred in India in people with acute-on-chronic liver failure linked to single-ingredient preparations.[18][19]
- What the case reports show. A case series of five patients from Iceland and the US found jaundice, nausea, lethargy, itching and abdominal discomfort after 2 to 12 weeks, usually a cholestatic or mixed pattern, with liver tests normalising within 1 to 5 months in four of the five.[20] A 2026 scoping review of 13 publications (25 patients) described the same pattern. It found one case of acute liver failure requiring transplant and three deaths in people with pre-existing cirrhosis, and concluded that patients with advanced chronic liver disease should avoid ashwagandha.[21] Case reports cannot tell us how common this is.
- Stop and seek advice if you develop yellowing of the skin or eyes, dark urine, nausea, vomiting, unusual tiredness, weakness, stomach pain or loss of appetite. The TGA also notes that sudden vomiting or diarrhoea after only one or two doses may be an acute reaction rather than liver damage, and also calls for stopping the product and seeing a doctor.[19]
- Avoid it if you have or have had liver problems, as the TGA advises as a precaution.[19] Some Australian reports involved products bought online from overseas, which the TGA does not regulate for quality, safety or effectiveness.[18]
- Tolerability in trials. A 2026 systematic review of 23 randomised trials (2,317 healthy adults) of standardised root extracts at 125 to 600 mg a day, for up to 180 days, found liver, kidney, blood, hormone and cardiovascular markers stayed within normal ranges and no serious adverse events attributable to the extract. Mild effects (stomach upset, headache, transient drowsiness) occurred in both treatment and comparison groups. The authors note limited data beyond 180 days and that case reports mostly involved non-standardised or multi-ingredient products.[17] Short trials in people without liver disease cannot rule out a rare reaction.
- Thyroid and adrenal effects. Published case reports describe thyrotoxicosis presenting with a fast heart rhythm,[24] and suppression of the adrenal axis after more than a year of roughly 950 mg a day.[23] A 2026 critical review lists endocrine effects among potential adverse effects.[22] These are single case reports (D: weak), but they are a reason to tell your doctor if you take thyroid medicine, have a thyroid condition or take corticosteroids.
- Other medicines. We found no high-quality interaction trials. Transient drowsiness was reported in some trials, and a small average fall in glucose was seen in one analysis.[16][17] It is reasonable to ask your pharmacist before combining it with sedatives, sleep medicines, diabetes medicines, thyroid medicines or immunosuppressants. This is a precaution based on mechanism, not a proven interaction.
- Pregnancy and breastfeeding. There is insufficient human evidence (F). A 2026 review found the claims of harm to pregnancy to be inconclusive and based partly on historical reports, but also found a need for high-quality studies.[25] The TGA requires a pregnancy warning statement on the labels of certain ashwagandha preparations.[18] Avoid it unless your doctor advises otherwise.
- Children and adolescents: do not give ashwagandha to children unless a doctor recommends it.
- Before surgery: mention any herbal supplement to your anaesthetist or surgeon.
Australian regulatory status
Ashwagandha is a permitted ingredient in listed medicines (AUST L). Listing means the sponsor certifies that the product uses permitted ingredients and is made to required quality standards. It is not the same as the TGA assessing whether the product works, which applies to registered medicines (AUST R).[18] The TGA said in 2024 that if further evidence emerged, regulatory actions such as label warning statements could be considered.[19] Check the TGA safety pages for the latest position before relying on this section.
Who might reasonably try it?
- Possibly reasonable, after a conversation with your doctor or pharmacist: otherwise-healthy adults with everyday stress or mild sleep difficulty who have already tried sleep, activity and stress-management basics, who have no liver problem, who are not pregnant or breastfeeding, and who take no interacting medicines. Treat it as a time-limited trial of about 8 weeks with a clear goal, and stop if there is no benefit.
- Probably not worth it as a main strategy: people hoping for muscle gain, testosterone changes, blood glucose control, or treatment of depression or an anxiety disorder.
- Avoid or get individual advice first: any current or past liver disease, or abnormal liver tests; pregnancy or breastfeeding; thyroid disease or thyroid medicine; people on corticosteroids, sedatives, diabetes medicines or immunosuppressants; people with an autoimmune condition; those awaiting surgery; and anyone under 18.
How to judge an ashwagandha product
We do not recommend brands. If you and your clinician decide a supplement is worth trying, check:
- AUST L (or AUST R) number on the label, which shows it is on the ARTG. Be cautious about products bought online from overseas, which the TGA does not regulate.[18]
- Plant part and extract: root, leaf, or root-and-leaf, and the extract ratio. Most trials used standardised root extract, so a leaf-containing or whole-plant product is not what was tested.
- Milligrams of extract per dose and how that compares with the trial range (roughly 125 to 600 mg a day), not just the “equivalent dry root” figure.
- Single-ingredient products are easier to interpret than blends. Several case reports involved multi-ingredient formulas, which makes the cause harder to pin down.
- Claims: be wary of labels or ads promising to treat anxiety or depression, balance hormones, or boost testosterone. The evidence does not support broad claims like these, and therapeutic advertising in Australia is restricted.
- Stopping rules: know the liver warning symptoms above before the first dose.
Our evidence grade
Letter grades describe confidence in the answer, not how good the supplement is. A high grade can support benefit or no meaningful benefit, and a low grade does not prove that something is ineffective.
| Claim | Grade | Why |
|---|---|---|
| Reduces self-reported stress and anxiety in adults with stress (about 250–600 mg a day of standardised root extract, about 8 weeks) | C: limited | Several pooled analyses favour ashwagandha, but trials are small and short, heterogeneity is very high (I² up to 94%), one analysis found no effect on perceived stress, and the authors of one rated certainty as low |
| Lowers cortisol | B: moderate | Direction of effect is consistent in two meta-analyses and in several trials. It is a laboratory marker, and the size of the effect varies between analyses |
| Improves sleep quality or sleep-onset time | C: limited | Five small trials (400 participants). Larger effects in insomnia, at 600 mg a day or more and after 8 or more weeks, but few trials and limited replication |
| Treats or prevents depression | D: weak | One recent analysis with implausibly large effects; depression was usually a secondary outcome |
| Improves memory, attention or executive function | C: limited | A 2026 meta-analysis of 20 trials found small gains, but populations and tests were mixed and results need replication |
| Improves aerobic performance or VO2max | C: limited | Meta-analyses of 13 and 4 trials. Heterogeneity is high, and the prediction interval crossed zero |
| Adds strength or muscle during resistance training | D: weak | Three trials (161 people). Significance was lost under a conservative method and depended on one trial. Certainty low to very low |
| Raises testosterone | C: limited | Small increases in pooled data and one crossover trial. They stay in the normal range, and no clinical benefit has been shown |
| Improves sexual function or fertility | D: weak | Evidence mixes animal and human research. The crossover trial in men found no significant between-group change in sexual well-being |
| Lowers blood glucose | D: weak | Fasting glucose fell by about 3 mg/dL with substantial heterogeneity; HbA1c inconclusive. Authors rated certainty very low |
| Is well tolerated for up to about 6 months in healthy adults (125–600 mg a day) | B: moderate | A systematic review of 23 trials (2,317 participants) found no serious adverse events attributable to the extract, but with limited data beyond 180 days |
| Can rarely cause liver injury | B: moderate | A reproducible clinical pattern across case series and a scoping review, with a TGA safety review. We cannot tell how common it is |
| Affects thyroid or adrenal function | D: weak | Based on single case reports and mechanism |
| Is safe in pregnancy or breastfeeding | F: insufficient | Not enough suitable human research. Avoid unless advised by a doctor |
See how we grade on our Evidence Grading page.
References
- Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4115–4124. doi:10.1002/ptr.7598 · PubMed 36017529
- Arumugam V, Vijayakumar V, Balakrishnan A, Bhandari RB, Boopalan D, Ponnurangam R, et al. Effects of Ashwagandha (Withania somnifera) on stress and anxiety: a systematic review and meta-analysis. Explore (NY). 2024;20(6):103062. doi:10.1016/j.explore.2024.103062 · PubMed 39348746
- Albalawi AA. Dual impact of Ashwagandha: significant cortisol reduction but no effects on perceived stress — a systematic review and meta-analysis. Nutr Health. 2025;31(4):1395–1408. doi:10.1177/02601060251363647 · PubMed 40746175
- Alsanie SA, Alhodieb FS, Askarpour M. Effects of ashwagandha (Withania somnifera) on mental health in adults: a systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2026;97:103325. doi:10.1016/j.ctim.2026.103325 · PubMed 41644067
- Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843. doi:10.1371/journal.pone.0257843 · PubMed 34559859
- Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012;34(3):255–262. doi:10.4103/0253-7176.106022 · PubMed 23439798
- Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: a randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(37):e17186. doi:10.1097/MD.0000000000017186 · PubMed 31517876
- Salve J, Pate S, Debnath K, Langade D. Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults: a double-blind, randomized, placebo-controlled clinical study. Cureus. 2019;11(12):e6466. doi:10.7759/cureus.6466 · PubMed 32021735
- Langade D, Thakare V, Kanchi S, Kelgane S. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: a double-blind, randomized, parallel-group, placebo-controlled study. J Ethnopharmacol. 2021;264:113276. doi:10.1016/j.jep.2020.113276 · PubMed 32818573
- Li X, Li H, Yao S, Hou Y, Chi A. Effects of Withania somnifera (Ashwagandha) supplementation on exercise performance: a systematic review and three-level meta-analysis. Nutrients. 2026;18(12):1915. doi:10.3390/nu18121915 · PubMed 42356302
- Pérez-Gómez J, Villafaina S, Adsuar JC, Merellano-Navarro E, Collado-Mateo D. Effects of Ashwagandha (Withania somnifera) on VO2max: a systematic review and meta-analysis. Nutrients. 2020;12(4):1119. doi:10.3390/nu12041119 · PubMed 32316411
- Lee JC, Heo AS. Adjunctive Ashwagandha (Withania somnifera) supplementation and resistance-training adaptations in healthy adults: a systematic review and random-effects meta-analysis of muscular strength, chest circumference, and body composition. Nutrients. 2026;18(17):2815. doi:10.3390/nu18172815 · PubMed 42738987
- Zhu X, Zeng Q, Lei Y, Xu D. Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis. Front Pharmacol. 2026;17:1799467. doi:10.3389/fphar.2026.1799467 · PubMed 42199854
- Lopresti AL, Drummond PD, Smith SJ. A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males. Am J Mens Health. 2019;13(2):1557988319835985. doi:10.1177/1557988319835985 · PubMed 30854916
- Roy D, Ghosh M, Roy D, Sharma N, Bhatia R, Rangra NK, et al. Effects of Ashwagandha on reproductive health: a systematic review of sex-specific hormonal and fertility outcomes. Phytother Res. 2026;40(8):4813–4832. doi:10.1002/ptr.70128 · PubMed 41249015
- Farrin N, Nikparast A, Yadegari M, Sohrabnavi A, Pourreza S, Sohouli MH, et al. The effects of Ashwagandha (Withania somnifera) supplementation on fasting blood glucose and HbA1c: a systematic review and dose-response meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2026;241:113529. doi:10.1016/j.diabres.2026.113529 · PubMed 42641800
- Coope OC, Willems MET, Levington A, Tallon MJ, Roman-Viñas B, Spurr TJ. Back to the roots: safety and tolerability of standardised ashwagandha (Withania somnifera) root extract in healthy adults — a systematic review of biomarkers and adverse events. Pharmaceuticals (Basel). 2026;19(5):725. doi:10.3390/ph19050725 · PubMed 42198398
- Therapeutic Goods Administration. Withania somnifera (Ashwagandha) and very rare risk of liver injury. Medicine Safety Update. Published 7 July 2026. tga.gov.au
- Therapeutic Goods Administration. Medicines containing Withania somnifera (Withania, Ashwagandha): safety advisory (February 2024), and Herbal preparations containing Withania somnifera: consumer safety alert (updated 2026). tga.gov.au (2024 advisory) · tga.gov.au (2026 consumer alert)
- Björnsson HK, Björnsson ES, Avula B, Khan IA, Jonasson JG, Ghabril M, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825–829. doi:10.1111/liv.14393 · PubMed 31991029
- McIntyre D, Nguyen P, Kim Y, Meyer B, Salloum M. Ashwagandha (Withania somnifera)-associated liver injury: a scoping review of clinical characteristics and safety considerations. Cureus. 2026;18(5):e109764. doi:10.7759/cureus.109764 · PubMed 42367407
- Kumar A, Sah BK, Ahmad F, Jamwal V, Sahu SK. Potential adverse effects of Ashwagandha: a critical review of preclinical and clinical evidence. Phytother Res. 2026;40(8):4913–4931. doi:10.1002/ptr.70158 · PubMed 41502355
- Javid J, Kunnuru SR, Anne B, Muskan S. From herbal hope to hormonal havoc: chronic ashwagandha use and HPA axis suppression. Endocrinol Diabetes Metab Case Rep. 2026;2026(1):EDM250076. doi:10.1530/EDM-25-0076 · PubMed 41553875
- Kamal HI, Patel K, Brdak A, Heffernan J, Ahmad N. Ashwagandha as a unique cause of thyrotoxicosis presenting with supraventricular tachycardia. Cureus. 2022;14(3):e23494. doi:10.7759/cureus.23494 · PubMed 35475098
- Tallon MJ, Koturbash I, Blum JL. A systematic and ethnobotanical review of Ashwagandha’s (Withania somnifera) teratogenic and abortifacient potentials. Phytother Res. 2026;40(8):4737–4758. doi:10.1002/ptr.70079 · PubMed 40887707
This article is general educational information, not personal medical advice. Talk to your doctor or pharmacist before starting a supplement, especially if you take regular medicines, have liver, thyroid or adrenal problems, are pregnant or breastfeeding, or are under 18. Evidence for Supplements does not accept payment or free products from supplement manufacturers for reviews.
Medical Disclaimer · Editorial Policy · Corrections Policy · Contact